drugset / Trial / NCT06791824
Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, phase IB/II clinical study to evaluate the safety, tolerability and preliminary efficacy of CM313(SC) injection in patients with relapsed/refractory aplastic anemia
Timeline
- Start
- 2025-03
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUMROTATUG | Monoclonal antibody | — | Subcutaneous |